GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GRAVITAS-309
- Sponsors Incyte Corporation
- 22 Jan 2019 According to an Incyte Corporation media release, results are expected in 2019.
- 22 Jan 2019 According to an Incyte Corporation media release, first patient has been treated.
- 12 Sep 2018 Planned End Date changed from 31 Dec 2021 to 17 Oct 2023.